Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
Regulation of gene expression in
2022-01-11

Regulation of gene expression in mammalian cells is governed by the epigenetic machinery, which includes several distinctive yet entangled branches. DNA and histone modifying enzymes, non-coding regulatory RNAs, and ATPase-dependent chromatin remodeling proteins all contribute to the dynamic alterat
-
HO acted as an intracellular defender against oxidative
2022-01-11

HO-1 acted as an intracellular defender against oxidative stress-induced cell damage. To elucidate the effects of HO-1 in ropivacaine-induced cytotoxicity in neuronal cells, HO-1 activity was inhibited using a specific HO-1 inhibitor zinc protoporphyrin, ZnPP. Our results indicate that ZnPP treatmen
-
In first wave first generation drugs
2022-01-11

In 2013, first-wave, first-generation drugs telaprevir and boceprevir was the first protease inhibitors (PIs) incorporated in Brazilian Clinical Guidelines for the treatment of patients infected with HCV Piperlongumine australia 1. Based on this 2013 Clinical Guideline, telaprevir could be used for
-
g-quadruplex Human immunodeficiency virus type HIV is respon
2022-01-11

Human immunodeficiency virus type 1 (HIV-1) is responsible for the g-quadruplex pandemic; notification is compulsory in Brazilian blood banks since 1988. From 1980 to 2016, the Brazilian MH reported 882,810 HIV/AIDS cases, with 52.3% in the southeast region. HIV/HCV co-infection has been associated
-
br Material and methods br Results br Discussion HBV
2022-01-11

Material and methods Results Discussion HBV develops several strategies to suppress antiviral immune responses. Here, we used a bifunctional siRNA molecule to silence HBx and activate RIG-I, which induced HBV inhibition partly mediated by RIG-I in HBV-carrier mice. Furthermore, this 3p-siHB
-
Failure of antioxidant defenses to remove exogenous ROS prod
2022-01-11

Failure of antioxidant defenses to remove exogenous ROS produced by redox cycling chemicals either by being inhibited by those compounds or overwhelmed by an excess ROS, will disrupt the balance between antioxidant/prooxidant system within the organisms leading to oxidative damage (Livingstone, 2003
-
The pharmacokinetics of was obtained in mouse
2022-01-11

The pharmacokinetics of was obtained in mouse, rat and dog to determine if it had a suitable profile to investigate the effects of the GPR120 mechanism (). had an adequate half-life, low clearance in all 3 species, and high blood levels and bioavailability. The low volume of distribution (V) indicat
-
In order to elucidate the
2022-01-11

In order to elucidate the mechanisms behind the observed changes in metabolic activity in the cardiomyoblasts we investigated changes in gene and protein expression subsequent to treatment with PSN632408 with or without concurrent exposure to palmitate. Activating GPR119 in basal and high palmitate
-
Mesoridazine Besylate synthesis br FXR Agonists Azepinol b
2022-01-11

FXR Agonists Azepinol[4,5-b]indole 1 (hEC50=600nM, efficacy (eff)=100%) was identified as a FXR agonist lead from a high-throughput screening effort. Structure–activity relationship (SAR) studies around the azepine ring demonstrated that dialkyl substitution at C-1 led to a 30-fold improvement in
-
The first phase of insulin
2022-01-10

The first phase of insulin secretion is due to calcium signaling because of glucose sensing, increased cytoplasmic ATP levels, cellular depolarization, calcium influx and activation of calcium sensing molecules that eventually causes the fusion of the insulin granules to plasma membrane (exocytosis)
-
The H R antagonist cimetidine Tagamet became the first
2022-01-10

The H2R antagonist cimetidine (Tagamet™) became the first billion-dollar drug in the 1980s for the treatment of peptic ulcer disease. Other H2R antagonists include ranitidine, famotidine, nizatidine, and zolantidine, the latter showing good BBB penetration with a steady-state brain/blood ratio of 1.
-
Ethacrynic Acid mg This study was supported by the Finance
2022-01-10

This study was supported by the Finance Department Foundation of Jilin Province (3D5178963428). Introduction Breast cancer is one of the leading cause of death in women worldwide [1,2]. Due to recent advances of combined therapies, survival rate of breast has improved significantly. However, bre
-
Recently the spectrin cytoskeleton a deformable actin
2022-01-10

Recently, the spectrin cytoskeleton, a deformable actin-associated network, has been identified as a modulator of Yki function, potentially acting both apically and basally in different cell types [75•, 76•, 77•]. Several mechanisms have been proposed, including regulation via Crb/Ex tethering [], t
-
With able to modulate inflammation and effect obesity relate
2022-01-10

With ω3 able to modulate inflammation and effect obesity-related outcomes, it is of interested that two G-protein coupled receptors (GPCR), GPR120 and GPR40, were recently deorphanized and shown to recognize ω3 acids (docosahexaenoic, C22:6; eicosapentaenoic, C20:4; and α-linolenic, C18:3), as well
-
br Acknowledgements We thank the support
2022-01-10

Acknowledgements We thank the support of the National Natural Science Foundation of China (NSFC) project 81501342 and support from the Disciplinary Group of Oncology and Immunology program of Xinxiang Medical University. Introduction First described as a new clinical entity in 1981, the Acqui
15620 records 549/1042 page Previous Next First page 上5页 546547548549550 下5页 Last page